InsidersTradesSigma
Follow the Immucell CORP share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Immucell CORP has recorded 25 reports. Market capitalisation: €100.9m. The latest transaction was reported on 24 March 2026 (Levée d'options). Among the most active insiders: Tomsche David Scott. The full history is openly available.
25
Insider Decl.
n/a
Thresholds
€51,040
10 ops.
Buy Volume
€92,012
11 ops.
Sell Volume
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,513 of 29,062 companies
27.3
score / 100
Value25
Quality29
FCF yld1.2%
Earn yld-1.0%
EV/EBITDA52.6x
ROE-1.9%
Gross mgn41%
Net mgn-3.8%
Debt/EBITDA6.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 March 2026
Declarations25 total
25,000 shares@ US$5.840.23% mcap50.0% of flowCommon Stock, par value $.01 per shareSEC:0001437749-26-009661:0
24,052 shares@ US$6.070.23% mcap50.0% of flowCommon Stock, par value $.01 per shareSEC:0001437749-26-009661:1
3,598 shares@ US$5.04550.1% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036913:0
Canonical exit: 3 Mar 2026 (T+90)
3,708 shares@ US$4.868649.9% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036794:0
Canonical exit: 2 Mar 2026 (T+90)
1,633 shares@ US$4.767.2% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036477:0
Canonical exit: 23 Feb 2026 (T+90)
3,530 shares@ US$4.81100.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-25-054188:0
1,000 shares@ US$6.32100.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-25-053904:0
Canonical exit: 10 Sept 2025 (T+90)
2,186 shares@ US$3.558.1% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-074326:0
6,005 shares@ US$3.5522.1% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-072552:0
10,000 shares@ US$3.5536.9% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-071759:0
2,017 shares@ US$3.5677.6% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-070559:0
3,100 shares@ US$4.754115.9% of flowCommon stock $0.10 per value per shareSEC:0001213900-23-074246:0
400 shares@ US$5.202.2% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:0
306 shares@ US$7.682.7% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-22-055334:0
100 shares@ US$8.270.0014% mcap19.5% of flowCommon stock $0.10 per value per shareSEC:0001213900-22-033261:0
1,000 shares@ US$8.000.014% mcap100.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-22-032625:0
Canonical exit: 11 Sept 2022 (T+90)
200 shares@ US$8.350.0029% mcap40.2% of flowCommon Stock, par valude $0.10 per shareSEC:0001213900-22-028008:0
200 shares@ US$8.350.0029% mcap40.2% of flowCommon Stock, par value $0.10 per shareSEC:0001213900-22-027891:0
1,000 shares@ US$5.840.0096% mcap100.0% of flowCommon Stock, par value $0.10 per shareSEC:0001213900-22-012143:0
3,845 shares@ US$7.08100.0% of flowCommon Stock, par value $0.10 per shareSEC:0001213900-21-031186:0
1,904 sharesCommon Stock, par value $0.10 per shareSEC:0001547522-16-000202:0
Canonical exit: 28 Apr 2016 (T+90)
2,857 sharesCommon Stock, par value $0.10 per shareSEC:0001547522-16-000204:0
Canonical exit: 28 Apr 2016 (T+90)
6,666 sharesCommon Stock, par value $0.10 per shareSEC:0001547522-16-000206:0
Canonical exit: 28 Apr 2016 (T+90)
4,761 sharesCommon Stock, par value $0.10 per shareSEC:0001547522-16-000208:0
Canonical exit: 28 Apr 2016 (T+90)
4,761 sharesCommon Stock, par value $0.10 per shareSEC:0001547522-16-000208:1
Canonical exit: 28 Apr 2016 (T+90)
25 of 25 declarations
关于 Immucell CORP
ImmuCell Corp /DE/（股票代码：ICCC）是一家在美国纳斯达克上市的公司，专注于动物健康，更具体地说是小牛生物制品。该公司成立于1982年，并于1987年上市。在1991年获得美国农业部批准销售First Defense®后，该公司在1990年代后期将其战略重点转向奶牛和肉牛应用。其总部位于缅因州波特兰。ImmuCell仍然是一个利基运营商，而不是一个广泛的动物健康平台，其产品组合以少数核心产品和强大的技术专业化为中心。（[sec.gov](https://www.sec.gov/Archives/edgar/data/811641/000121390016011870/f10k2015_immucellcorp.htm?utm_source=openai)) 公司主要业务是开发、制造和商业化First Defense®系列产品，旨在为新生奶牛和小肉牛提供针对腹泻（新生犊牛腹泻）的即时免疫保护。管理层将这种疾病定位为美国养牛业的主要经济负担，并将First Defense®视为一种获得美国农业部许可的生物制品，用于预防腹泻。ImmuCell还继续开发Re-Tain®，这是一种治疗泌乳奶牛亚临床乳腺炎的候选药物，尽管该项目经历了监管和会计相关的挫折，包括最近的资产减记。（[immucell.com](https://immucell.com/investors/)) 从竞争角度来看，ImmuCell的差异化来自于专有的生物技术知识及其在超免疫牛初乳加工方面的规模。该公司表示，它是唯一能够商业化超免疫牛初乳的动物健康公司，这支持了其在专业、高壁垒利基市场中的定位。ImmuCell并非作为多元化的动物健康企业集团参与竞争，而是在产品功效、制造能力和农场经济价值方面进行竞争。其市场敞口主要与北美奶牛和肉牛生产相关，在该市场中，小牛存活率、生产力和对 antibiotics 的依赖减少推动了产品的采用。（[immucell.com](https://immucell.com/about-immucell/our-purpose/?utm_source=openai)) 最近的发展表明运营方面有显著改善。在2026年3月发布的涵盖2025年全年业绩的报告中，ImmuCell报告产品销售额约为27.6 million美元，同比增长4.3%，毛利率为41.4%（2024年为30.0%），净营业收入为1.6 million美元。管理层将改善归因于销量增加、制造效率提高和价格实现改善，同时还指出与Re-Tain®和首席执行官过渡成本相关的一次性项目。该公司还强调了月平均产量的增加和对产量持续改进的关注。对于投资者而言，ICCC是美国一家纳斯达克上市的小盘动物健康公司，产品组合集中，利基市场具有防御性，其发展前景严重依赖于制造、商业化和监管开发方面的执行。（[immucell.com](https://immucell.com/wp-content/investor-assets/press-releases/2026/Rel2026-03-04-lttrhead.pdf))
